The gold standard in GLP-1 metabolic therapy. FDA-approved active ingredient, once-weekly injection, clinically proven weight management.
Peptides frequently paired with Semaglutide for enhanced outcomes. Reviewed by practitioners.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1/GIP agonist | Triple GLP-1/GIP/Glucagon agonist |
| Avg Weight Loss | ~15% body weight | ~22.5% body weight | ~24% body weight (Phase 2) |
| FDA Status | FDA Approved (2021) | FDA Approved (2023) | Phase 3 Trials |
| Dosing | Weekly subcutaneous | Weekly subcutaneous | Weekly subcutaneous |
| Half-Life | ~7 days | ~5 days | ~6 days |
| Clinical Data | STEP 1-4 (n=4,500+) | SURMOUNT 1-4 (n=5,000+) | Phase 2 (n=338) |
Yes — the active pharmaceutical ingredient is identical: semaglutide. Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management) are brand names manufactured by Novo Nordisk. Our formulation is compounded by a licensed 503A pharmacy using the same molecule at equivalent purity, verified by independent HPLC testing.
Most patients report noticeable appetite reduction within the first 1–2 weeks. Measurable weight loss typically begins by week 4. The STEP 1 trial showed an average of 15% body weight loss over 68 weeks. Your clinician will titrate your dose gradually over 16 weeks to minimize side effects.
Semaglutide is commonly prescribed alongside metformin. However, it can interact with insulin and sulfonylureas (increasing hypoglycemia risk), oral contraceptives (delayed absorption), and warfarin. Your reviewing clinician will check for interactions based on your health intake.
Store reconstituted peptide in the refrigerator at 36–46°F (2–8°C). Do not freeze. Protect from light. Once reconstituted, use within 30 days. Unreconstituted vials can be stored at room temperature for up to 28 days but refrigeration is recommended for maximum potency.
Add the included bacteriostatic water to the lyophilized powder using an insulin syringe. Swirl gently — do not shake. Draw your prescribed dose and inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites. Detailed reconstitution instructions, dosing calculator, and video tutorial are included with your Matter Protocol Kit (free with first order).
If you miss a dose and it has been less than 48 hours since your scheduled injection, take it as soon as possible. If more than 48 hours have passed, skip the missed dose and resume your regular schedule. Do not double up on doses. Consistent timing gives the best results.
Bloodwork is not strictly required but is strongly recommended. A baseline panel helps your clinician tailor your protocol and track progress. We offer lab panels through our diagnostic testing partners if you don't have recent results.
Alcohol is not contraindicated for most peptides but should be consumed in moderation. Alcohol can impair recovery and reduce the effectiveness of growth hormone and repair peptides. We recommend limiting consumption, especially on injection days.
Effects vary by peptide. Some benefits (like tissue repair from BPC-157) may persist after completing a cycle. Others (like appetite suppression from GLP-1 agonists) will diminish. Your clinician can help develop a tapering and maintenance strategy.
After checkout, you'll complete a brief health intake form (about 2 minutes). Once saved to your Apotheca account, you never need to fill it out again for future orders). A licensed clinician reviews your protocol using Gabriel clinical intelligence. Most protocols are approved same-day. If not approved, you receive a full refund. Your compounded formulation ships within 48 hours of approval.
Apotheca is analyzing ingredient interactions, stacking compatibility, and timing recommendations for Semaglutide. This data will be available soon.
Semaglutide has the most comprehensive evidence base of any weight management compound.
FDA-approved as Ozempic (diabetes), Wegovy (weight management), Rybelsus (oral). Label expanded March 2024 for CV risk reduction.
Synthesized from peer-reviewed studies in our corpus of 140,000+ research papers. Each finding is cited to its source publication.
